CA2343572C - Marqueur au niveau du gene recepteur de la vitamine d, utilise pour la determination de la sensibilite au cancer du sein - Google Patents
Marqueur au niveau du gene recepteur de la vitamine d, utilise pour la determination de la sensibilite au cancer du sein Download PDFInfo
- Publication number
- CA2343572C CA2343572C CA002343572A CA2343572A CA2343572C CA 2343572 C CA2343572 C CA 2343572C CA 002343572 A CA002343572 A CA 002343572A CA 2343572 A CA2343572 A CA 2343572A CA 2343572 C CA2343572 C CA 2343572C
- Authority
- CA
- Canada
- Prior art keywords
- breast cancer
- vitamin
- gene
- vdr
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 162
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 162
- 108050000156 vitamin D receptors Proteins 0.000 title claims abstract description 162
- 239000003550 marker Substances 0.000 title description 22
- 102000009310 vitamin D receptors Human genes 0.000 claims abstract description 126
- 238000000034 method Methods 0.000 claims abstract description 75
- 238000011161 development Methods 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 101150084240 VDR gene Proteins 0.000 claims description 40
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 40
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 108700028369 Alleles Proteins 0.000 claims description 23
- 238000003752 polymerase chain reaction Methods 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 230000029087 digestion Effects 0.000 claims description 12
- 108700008625 Reporter Genes Proteins 0.000 claims description 10
- 230000008901 benefit Effects 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- 108700042354 Vitamin D Response Element Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 13
- 230000004043 responsiveness Effects 0.000 abstract description 11
- 102000053602 DNA Human genes 0.000 description 66
- 108020004414 DNA Proteins 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 30
- 239000000523 sample Substances 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 239000013615 primer Substances 0.000 description 18
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000556 agonist Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000007834 ligase chain reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 239000003155 DNA primer Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000036365 BRCA1 Human genes 0.000 description 3
- 108700040618 BRCA1 Genes Proteins 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700010154 BRCA2 Genes Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- -1 hormones Chemical class 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000735 select agent Toxicity 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne une méthode de détermination de la prédisposition d'un individu au cancer du sein, du développement du cancer du sein et/ou de la réactivité au traitement du cancer du sein. Ledit procédé consiste à déterminer le génotype du récepteur de la vitamine D de l'individu, la prédisposition de l'individu au cancer du sein, le développement du cancer du sein et/ou la réactivité au traitement du cancer du sein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10044898P | 1998-09-15 | 1998-09-15 | |
| US60/100,448 | 1998-09-15 | ||
| PCT/CA1999/000853 WO2000015835A2 (fr) | 1998-09-15 | 1999-09-15 | Marqueur au niveau du gene recepteur de la vitamine d, utilise pour la determination de la sensibilite au cancer du sein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2343572A1 CA2343572A1 (fr) | 2000-03-23 |
| CA2343572C true CA2343572C (fr) | 2008-01-22 |
Family
ID=22279822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002343572A Expired - Fee Related CA2343572C (fr) | 1998-09-15 | 1999-09-15 | Marqueur au niveau du gene recepteur de la vitamine d, utilise pour la determination de la sensibilite au cancer du sein |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1114180A2 (fr) |
| AU (1) | AU5723299A (fr) |
| CA (1) | CA2343572C (fr) |
| WO (1) | WO2000015835A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270094B1 (en) | 1999-03-26 | 2001-08-07 | William F. Campbell | Multi-purpose wire dispensing cart |
-
1999
- 1999-09-15 AU AU57232/99A patent/AU5723299A/en not_active Abandoned
- 1999-09-15 WO PCT/CA1999/000853 patent/WO2000015835A2/fr not_active Application Discontinuation
- 1999-09-15 CA CA002343572A patent/CA2343572C/fr not_active Expired - Fee Related
- 1999-09-15 EP EP99944189A patent/EP1114180A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000015835A3 (fr) | 2000-07-13 |
| CA2343572A1 (fr) | 2000-03-23 |
| AU5723299A (en) | 2000-04-03 |
| EP1114180A2 (fr) | 2001-07-11 |
| WO2000015835A2 (fr) | 2000-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henson et al. | The retinoblastoma gene is involved in malignant progression of astrocytomas | |
| EP0821733B1 (fr) | Marqueurs genetiques pour le cancer du sein et des ovaires | |
| US9909189B2 (en) | Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues | |
| JP2004159661A (ja) | 唾液分析による新生物の検出 | |
| AU720500B2 (en) | Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 | |
| JP2009165473A (ja) | 癌 | |
| US6444427B1 (en) | Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof | |
| US20060040263A1 (en) | Marker at the androgen receptor gene for determining breast cancer susceptibility | |
| CA2343572C (fr) | Marqueur au niveau du gene recepteur de la vitamine d, utilise pour la determination de la sensibilite au cancer du sein | |
| EP1394268A1 (fr) | HNF1alpha en tant que suppresseur de tumeur et utilisation thérapeutiques et diagnostiques de celle-ci | |
| CA2343049A1 (fr) | Combinaison de marqueurs au niveau des genes recepteurs des oestrogenes et de la vitamine d, ou equivalents de ces derniers, pour le pronostic d'une reponse au traitement de l'osteoporose | |
| WO2001073116A2 (fr) | Methode permettant de determiner la probabilite d'etre atteint d'osteoporose et/ou une faible densite osseuse, et reactifs destines a cette methode | |
| JP2001518311A (ja) | 遺伝子座の階層化による疾病の関連づけ | |
| AU760490B2 (en) | Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 | |
| WO2002006522A2 (fr) | Marqueur du gene du recepteur de l'oestrogene permettant de determiner la predisposition a une densite osseuse faible | |
| WO2005033339A1 (fr) | Polymorphisme du gene du recepteur de type toll-3 humain utilise en tant que marqueur du facteur herite d'une maladie allergique et utilisation de ce marqueur | |
| JP2007503806A (ja) | ヒト肥満感受性遺伝子およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160915 |